Pluristem Therapeutics Inc. announced the completion of 3 and 6 month clinical follow-ups. Data from its two open label, dose escalation, Phase I clinical trials conducted in the United States and Germany suggests that Pluristem’s placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life and is potentially effective in treating patients and reducing amputations in those suffering from critical limb ischemia, the end-stage of peripheral artery disease.
Among the 27 patients treated with PLX-PAD, only one amputation was recorded, representing a 3.7% amputation rate. This represents a 75% reduction in amputation rate compared to historical data, which varies from 20% to 40%.
